HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crack-Down On Homeopathic Products Pushed By EU Science Advisory Council

This article was originally published in The Pink Sheet

Executive Summary

European Academies Science Advisory Council urges “standardized, knowledge-based” regulatory framework for homeopathic products, similar to requirements for medicinal products in the EU. The umbrella organization representing 29 European scientific bodies says claims for the products are too often “implausible” and threaten consumer health.

You may also be interested in...



NHS England Tackles Use Of ‘Ineffective And Dangerous’ Medicines

The National Health Service in England has drawn up a proposed list of “ineffective and dangerous” medicines that should not be routinely used in primary care, in a move to conserve resources and improve patient outcomes. They include products containing substances like fentanyl, tadalafil and trimipramine, as well as homeopathics and traditional herbal medicines.

OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC

US trade regulator will require an "inherent contradiction" for homeopathic OTC labels: disclaimers to FDA-compliant label indications indicating a lack of scientific evidence that the product works.

J&J’s Discontinuation Of Johnson’s Baby Powder Linked To April Federal Court Ruling

Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.

Topics

UsernamePublicRestriction

Register

SC142321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel